Close Menu

NEW YORK (GenomeWeb) ­– Abbott reported Wednesday morning that first quarter sales in its Diagnostics business grew 2 percent year over year, buoying flat overall revenue growth for the company.

For the three months ended March 31, Abbott reported overall Q1 revenues of $4.89 billion, down a fraction of a percent from Q1 last year, but up 5 percent year over year excluding unfavorable foreign currency effects. The company beat the consensus Wall Street estimate of $4.78 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.